Under construction – not a live service
Sign in
CompletedPhase 2

Does Tranexamic acid, a medicine used in treating and preventing bleeding problems, reduce the blood loos when it is injected directly into the hip joint after insertion of a total hip prosthesis

Key facts

Who runs it
Region Hovedstaden
Where
Denmark1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
100 people enrolled
Started
18 Oct 2022
Ended
20 Sept 2026
Type of study
Interventional
Record updated
11 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • ≥ 18 years
  • Undergoing surgery for unilateral total hip arthroplasty
  • Able to give ones consent either verbally or written

Who cannot take part

  • In treatment with the following anticoagulatia: ADP receptorinhibitors, vitamin-K antagonist(within 5-7 days before the operation). Factor Xa inhibitors, thrombine-inhibitors
  • Disseminated intravascular coagulation (DIC) or active thromboembolic disease
  • Active cancer disease
  • Reduced kidney function (GFR <45 ml/hour)
  • Operation performed in general anaesthesia
  • Patients who are not able to speak and understand Danish
  • Patients who refuse to receive blood products
  • Present acute thromboembolic event (DVT, AMI, cerebral infarction, pulmonary embolism)
  • Had one of the following type of trauma or surgeries in the affected hip: Hip fractures, periacetabulær osteotomy, femurosteotomy, trochanterostetomi
  • Rheumatic arthritis
  • Allergi to TXA
  • Use of oral anticonceptiva
  • Known with thrombophilia
  • Participated in a clinical trial within the last 30 days
  • Alcoholism and morphinism
  • Females: menstruation within the last 12 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

In this RCT-study we investigate the potential additive effect of intraarticular injected Tranexamic Acid (TXA) for the total blood loss in unilateralt total hip arthroplasty in addition to conventional treatment with IV TXA. The intervention group will be given IV TXA at the start of surgery + injection of TXA into the joint (end surgery) VS. TXA at the start of surgery + injection af equal volume of NaCl (placebo).Primary endpoint is total blood loss 24 hours after surgery.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Evaluation of intra articular Tranexamic acid for reduction of total blood loss in total hip arthroplasty
Record updated
11 December 2025